# Junta clínica — PT-pseudo_c9d31197c533 (tarea 1)

## Intervención 1 — INTAKE

*the record clerk; reads the file out loud and interprets nothing* · vuelta 1

Colleagues, this is the record as it arrived, field by field. I read it out and interpret nothing; everything after this is yours.

{
  "case_id": "PT-pseudo_c9d31197c533",
  "pid": "PT-pseudo_c9d31197c533",
  "task": 1,
  "psa": 10.92,
  "age": 61,
  "months": 1,
  "pirads": "5",
  "psad": 0.26,
  "psav": 1.16,
  "psap": 10.0,
  "vol": 42.0,
  "dre": "Nodus",
  "bx": "Positive",
  "cspca": 0.8727174,
  "medhx": "Hypertension, Osteoarthritis",
  "meds": "valsartan, lisinopril, paracetamol PRN",
  "notes": "PSA 10.92 ng/mL. PI-RADS 5. PSAD 0.26. Prostate volume 42 mL. DRE nodus. csPCa 0.87.",
  "pmhx": [
    "Hypertension",
    "Osteoarthritis"
  ],
  "allergies": [],
  "vitals": {
    "weight": "73 kg",
    "height": "172 cm",
    "bmi": "24.7",
    "bp": "125/92 mmHg",
    "hr": "75 bpm",
    "smoking": "Non-smoker",
    "last_dental": "3 yr ago",
    "flu_vax": "Sep 2024"
  },
  "enc_dept": "Urology - outpatient",
  "enc_date": "02 Feb 2025",
  "enc_ref": "Dr. R. Visser (GP)",
  "enc_type": "Re-evaluation - prior PCa diagnosis",
  "note_sections": [
    {
      "s": "Chief complaint",
      "t": "Persistent PSA elevation and confirmation of Gleason 4+3 carcinoma on prior biopsy bucket \"Positive\" warrant clinical reassessment."
    },
    {
      "s": "History",
      "t": "A 61-year-old retired bank clerk entered the diagnostic pathway in late 2023 due to elevated PSA levels. He is a non-smoker with a background of hypertension treated by valsartan and lisinopril, plus osteoarthritis managed with paracetamol PRN. Divorced, he resides in an assisted-living facility and enjoys tennis twice weekly, averaging 22 units of alcohol each week. With his daughter handling correspondence under consent, he recently completed baseline memory screening and a sleep clinic assessment for suspected obstructive sleep apnoea. A prior 12-core biopsy confirmed Gleason 4+3 disease. He experiences chronic lower urinary tract symptoms yielding an IPSS of 20/35, yet denies urinary retention, haematuria, unexplained weight loss, or bone pain. His overall condition remains stable."
    },
    {
      "s": "Physical examination",
      "t": "DRE — texture: moderately enlarged gland with a firm, discrete nodule palpable in the left peripheral zone; remainder symmetrically smooth without induration. General examination shows stable vital signs, unremarkable systemic findings, and no palpable lymphadenopathy or hepatosplenomegaly."
    }
  ],
  "occupation": "retired bank clerk",
  "marital": "Divorced",
  "living": "Lives in assisted-living facility",
  "next_of_kin": "Nephew",
  "recent_other": [
    "Memory clinic — baseline screening",
    "Sleep clinic — suspected obstructive sleep apnoea"
  ],
  "alcohol": "22 units / week",
  "exercise": "Tennis 2x/week",
  "ipss": "IPSS score: 20/35 (severe LUTS)",
  "admin": "Daughter manages communication; CC on letters with patient consent.",
  "mri_hospital": "Amsterdam UMC (location AMC)",
  "ct": null,
  "active_treatment_flag": 0
}

## Intervención 2 — INTAKE

*the record clerk; reads the file out loud and interprets nothing* · vuelta 1

And this is the same record as the reading form presents it — the panel the urologist sees up front, with the masked documents named but not shown.

You are a senior urologist reviewing a patient case. The structured clinical
record below is shown to you up front, exactly as in the reading form. Some
documents are not shown and must be pulled up via the available tools
(radiology / MRI report, pathology report, previous notes, laboratory
results, PSA history, and the family-history anamnesis) when you need to
consult them.

Case ID: PT-pseudo_c9d31197c533
Task: 1

Encounter: Urology - outpatient on 02 Feb 2025.
Referrer: Dr. R. Visser (GP).
Type: Re-evaluation - prior PCa diagnosis.

Clinical data (read-only — values loaded from the record):
  - 61-year-old male
  - PSA: 10.92 ng/mL
  - mpMRI — PI-RADS score: 5 (1–2 low · 3 equivocal · 4–5 high risk)
  - PSA density: 0.26 ng/mL²
  - PSA velocity: 1.16 ng/mL/yr
  - Prior PSA: 10.0 ng/mL
  - Prostate volume: 42.0 mL
  - Months since last PSA: 1
  - DRE findings: Nodus (Normal · Nodus · Benign · Suspicious · Abnormal · Negative · Not done)
  - Prior biopsy: Positive (None · Negative · ASAP/HGPIN · Positive)
  - csPCa predicted probability: 0.8727174 (clinically significant PCa = ISUP ≥ 2)

Medical history & medication:
  - Medical history: Hypertension, Osteoarthritis
  - Problem list / PMHx: Hypertension, Osteoarthritis
  - Current medication: valsartan, lisinopril, paracetamol PRN
  - Allergies: NKA
  - Additional notes: PSA 10.92 ng/mL. PI-RADS 5. PSAD 0.26. Prostate volume 42 mL. DRE nodus. csPCa 0.87.

Vitals: weight 73 kg, height 172 cm, BMI 24.7, BP 125/92 mmHg, HR 75 bpm. Smoking: Non-smoker.

Chief complaint: Persistent PSA elevation and confirmation of Gleason 4+3 carcinoma on prior biopsy bucket "Positive" warrant clinical reassessment.

History: A 61-year-old retired bank clerk entered the diagnostic pathway in late 2023 due to elevated PSA levels. He is a non-smoker with a background of hypertension treated by valsartan and lisinopril, plus osteoarthritis managed with paracetamol PRN. Divorced, he resides in an assisted-living facility and enjoys tennis twice weekly, averaging 22 units of alcohol each week. With his daughter handling correspondence under consent, he recently completed baseline memory screening and a sleep clinic assessment for suspected obstructive sleep apnoea. A prior 12-core biopsy confirmed Gleason 4+3 disease. He experiences chronic lower urinary tract symptoms yielding an IPSS of 20/35, yet denies urinary retention, haematuria, unexplained weight loss, or bone pain. His overall condition remains stable.

Physical examination: DRE — texture: moderately enlarged gland with a firm, discrete nodule palpable in the left peripheral zone; remainder symmetrically smooth without induration. General examination shows stable vital signs, unremarkable systemic findings, and no palpable lymphadenopathy or hepatosplenomegaly.

Patient info: retired bank clerk; Divorced; Lives in assisted-living facility.
Next of kin: Nephew.

Lifestyle: alcohol 22 units / week; exercise Tennis 2x/week; IPSS score: 20/35 (severe LUTS).

Recent other appointments: Memory clinic — baseline screening; Sleep clinic — suspected obstructive sleep apnoea.
Admin: Daughter manages communication; CC on letters with patient consent.

Information you can request via tools (the masked "Extended EHR view" — what
the urologist would actively pull up during the consult):
  - radiology / MRI report (full mpMRI prose behind the headline imaging values)
  - pathology report (any prior biopsy on record)
  - previous GP / urology consultation notes
  - laboratory results (full panel)
  - PSA history (trend / velocity beyond the headline value)
  - family history of prostate cancer (anamnesis)

Question:
Based on this patient's data, do you recommend biopsy?


One correction to that last paragraph before anybody acts on it: the documents this task actually serves are radiology_report, psa_trend, previous_notes, laboratory_results, plus the family-history anamnesis. There is NO pathology report to pull up in a task-1 biopsy decision — the prior-biopsy status on the panel above is all the pathology on record, and whatever the previous notes say about it. Nobody should ask for one, and nobody should quote one.

## Intervención 3 — EXPERT-STRUCTURED

*Expert 1, Extra-Trees on the structured panel only; opening bid with an error bar* · vuelta 1

Expert 1 here — the classifier that reads the structured panel and nothing else. My bid:

SUGGESTION: NO BIOPSY   p(biopsy) = 0.36
  uncertainty  +/- 0.12 epistemic (95% band 0.12-0.60); among patients I cannot tell apart the outcome was 0.94 of 1.00 mixed
  reliability  MODERATE ('supports' tier) — out-of-fold it was right 60% of the time over the 20 labelled cases in this tier

What moved me most, across the labelled series: prior positive biopsy, PI-RADS >= 4, no prior biopsy, pmhx_hypercholesterolaemia, suspicious DRE, number of comorbidities. I read 39 variables, all
from the panel — nothing from the mpMRI prose, the PSA trajectory, the previous notes or the
laboratory. Out-of-fold over 91 labelled cases: AUC 0.758, balanced
accuracy 0.625.

The final call is the chair's.

## Intervención 4 — EXPERT-COHORT

*cohort criterion; what the labelled series did in this exact situation* · vuelta 1

This patient's situation: prior positive biopsy. The panel alone does not answer, and that is the finding.

The criterion here is that the visible panel does not determine this decision: he already has a tissue diagnosis, so neither a high PI-RADS nor a rising PSA is new information. What decides it is the documented grade of the prior biopsy and the surveillance history, which live in the previous notes. Measured on the labelled series: none of the three panel
rules I carry for this situation (PSA >= 20, age >= 78, PI-RADS <= 2) applies to him, and among the
39 remaining labelled men in this situation no structured variable separates the two answers.

REGISTRAR: the previous notes are where this case is decided. Read them for the grade of the prior
biopsy (Gleason or ISUP), the number of biopsy sessions and their dates, and whether he is on a
surveillance protocol with a confirmatory biopsy due. Do not read this as 'defer' and do not read it
as 'biopsy'.

## Intervención 5 — EXPERT-LIBRARY

*case library; the closest labelled precedents and what the reading urologist did with them* · vuelta 1

The case library holds 49 labelled men in this same situation (Positive prior biopsy). The 3 closest by panel distance, and what the reading urologist did:
  1. distance 0.00 — IDENTICAL PANEL: this is the same case, already in the labelled series: PI-RADS 5, PSA 10.92, PSAD 0.26, age 61, DRE Nodus -> DEFER (clear). He wrote: "Advocate for curative treatment while unfavorable intermediate risk pc in young patient without significant comorbidity. IF he is cautious toward curative treatment, rep…"
  2. distance 0.81: PI-RADS 5, PSA 8.3, PSAD 0.215, age 66, DRE Suspicious -> DEFER (clear). He wrote: "This person should discuss curative treatment (younger patient with palpable, MRI-visible high-risk disease incl Gleason 5 findings). If not curative treatment for any r…"
  3. distance 1.07: PI-RADS 5, PSA 8.6, PSAD 0.202, age 68, DRE Nodus -> BIOPSY (clear). He wrote: "Patient reasonable to discuss curative treatment with (age 68, no very dramatic comorbidity, unfavorable intermediate risk disease). Considering he chose not curative tr…"

PRECEDENT: DEFER. The nearest precedent is this very patient, so the library returns what the reading urologist actually did with him. That is a record, not a judgement; out of sample this expert is worth only what the distance is worth.

What the precedents are FOR: they show what this urologist looks at and how he phrases the call. What they are NOT: facts about this patient. Nobody may cite a precedent's grade, PSA or MRI as if it were his.

## Intervención 6 — EXPERT-TRACE

*Expert 4, trace model; which documents the reading urologist opens and what he weighs in this situation* · vuelta 1

Expert 4 here — the model of how the reading urologist works a case like this. This patient is in the labelled series, so what follows is the reading urologist's own trace for him, not a prediction.

WHAT HE OPENS: radiology_report, psa_trend, previous_notes, laboratory_results.
WHAT HE WEIGHS: dre=important, bx=decisive, comorbidity=noted, pirads=important, vol=noted, psad=noted, age=important, fh=noted, psa=noted.
HOW SURE HE USUALLY IS: clear.

MODERATOR: that list of documents is the plan — exactly those, no more. Every document opened beyond what
he would open is scored against the conference as an unnecessary reveal; every document left closed
leaves a variable he weighed without its source. Attach the question each one must answer.

## Intervención 7 — EXPERT-EAU

*EAU guideline specialist; speaks only from the guideline text he retrieved* · vuelta 1

GUIDELINE
The retrieved guidelines discuss the use of MRI and biopsy in relation to PI-RADS scores and PSA density. The guideline suggests that a PI-RADS threshold of $\ge 3$ is used to trigger a biopsy, at the cost of missing a small number of mainly ISUP GG 2 cancers, especially in biopsy-naïve patients or in highly selected populations with a high prevalence of csPCa.

WHAT THE EXPERTS' BIDS DO NOT SETTLE
Expert-Structured's suggestion of no biopsy is based on a classifier that weighs variables present on the panel, but the guideline suggests that the decision is risk-adapted based on multiple factors, not just the presence of a prior positive biopsy. Expert-Cohort's finding that the prior positive biopsy means the panel alone does not determine the decision is consistent with the guideline's emphasis on documented prior diagnosis, but the guideline does not specify how the documented grade of the prior biopsy should weigh against the current imaging findings.

WHAT WE STILL NEED
The panel already contains the following known facts:
*   **Prior-biopsy status:** Positive (This is decisive as the guideline discusses repeat biopsy after a negative biopsy).
*   **PI-RADS:** 5 (This is a high-risk finding that the guideline links to biopsy consideration).
*   **PSA density:** 0.26 ng/mL² (This value is relevant as the guideline references PSA-D cut-offs).
*   **csPCa probability:** 0.8727174 (This indicates a high clinical suspicion).
*   **Prior biopsy grade:** Positive (The specific Gleason/ISUP grade from the prior biopsy is needed to assess risk according to the guideline's context).
*   **MRI prose:** The full mpMRI prose is needed to assess if it compares against an earlier study, as the guideline mentions this in relation to repeat biopsy.

## Intervención 8 — MODERATOR

*chairs the discussion; sets the open questions and assigns the documents* · vuelta 1

This case hinges on establishing the documented grade of the prior biopsy and the surveillance status detailed in the previous notes.

The documents for this session were fixed by EXPERT-TRACE; what I add is the question each one has to answer, and the open questions for the room.

REGISTRAR — pull these up, and answer exactly the question attached to each:
  radiology_report (get_mri_report) -> What is the lesion size and zone, extraprostatic extension, and comparison against an earlier study?
  psa_trend (get_psa_trend) -> What is the serial PSA value trend beyond the headline number?
  previous_notes (get_previous_notes) -> What is the management context, including the prior biopsy grade (Gleason/ISUP), number and dates of biopsy sessions, and surveillance plan?
  laboratory_results (get_lab_results) -> What are the full panel results, including free-PSA fraction, renal function, and haemoglobin?

OPEN QUESTIONS for this conference — these are what the decision hangs on:
  Q1. What is the documented Gleason or ISUP grade of the prior positive biopsy?
  Q2. Is the patient currently on a surveillance protocol with a confirmatory biopsy due?

## Intervención 9 — REGISTRAR

*the registrar who pulls up documents; reports what they say, nothing else* · vuelta 1

WHAT I FOUND
radiology_report
The lesion size and zone is approximately "18 x 14 x 12 mm" in the left peripheral zone, with no extraprostatic extension or seminal vesicle invasion identified. Comparison against an earlier study is "new".
psa_trend
The serial PSA value trend beyond the headline number is: {"date": "Dec 2023", "val": 4.5}, {"date": "Mar 2024", "val": 5.6}, {"date": "Jul 2024", "val": 7.0}, {"date": "Oct 2024", "val": 8.7}, {"date": "Feb 2025", "val": 10.92}.
previous_notes
The management context, including the prior biopsy grade (Gleason/ISUP), number and dates of biopsy sessions, and surveillance plan is: "Earlier tissue sampling established Gleason 4+3 disease. Hypertension remains well-managed through valsartan and lisinopril therapy."
laboratory_results
The full panel results, including free-PSA fraction, renal function, and haemoglobin are: PSA "10.9 ng/mL" on "09 Jan 2025", Free PSA "1.10 ng/mL" on "09 Jan 2025", "%Free PSA" "10%" on "09 Jan 2025", Haemoglobin "13.2 g/dL" on "09 Jan 2025", WBC "6.1 x10^9/L" on "09 Jan 2025", Platelets "171 x10^9/L" on "09 Jan 2025", Creatinine "97 umol/L" on "09 Jan 2025", eGFR ">60 mL/min/1.73m2" on "09 Jan 2025", Testosterone "9.3 nmol/L" on "09 Jan 2025", Alkaline phosphatase "81 U/L" on "09 Jan 2025", LDH "203 U/L" on "09 Jan 2025", HbA1c "6.3 %" on "09 Jan 2025".

WHAT I DID NOT OPEN
family-history anamnesis, because the previous notes already provided the relevant prior biopsy grade and surveillance context.

WHAT THIS SUPPORTS
Findings that argue FOR sampling this patient now:
PI-RADS 5 finding from the mpMRI report.
csPCa predicted probability of 0.8727174.
PSA velocity of 1.16 ng/mL/yr.

Findings that argue AGAINST sampling this patient now:
Prior biopsy established Gleason 4+3 disease.
The previous notes indicate no explicit surveillance protocol with a confirmatory biopsy due.

WHERE THIS LEANS
The findings point towards a high-risk scenario based on imaging and PSA kinetics, but the documented prior diagnosis complicates the immediate need for a new biopsy.
LEAN: unclear

## Intervención 10 — EXPERT-PSA

*Expert 2, PSA projector; the trajectory behind the headline PSA, with a conformal band* · vuelta 1

Expert 2 here — the PSA projector. I read only the serial PSA the registrar opened.

TRAJECTORY: INDETERMINATE (uncertain). Last value 10.92 ng/mL over 5 points spanning 14 months; velocity +5.47 ng/mL per year; doubling time about 11 months.
PROJECTION at 6 months: 13.4 ng/mL, conformal 95% band 3.9-46.8.

Read the band before the point: it is wide by construction, and I only call a direction when the whole
band clears the last value. This does not vote on the biopsy — a rising PSA in a man with a known
diagnosis is the disease behaving as known — it tells the chair how fast the number is moving.

## Intervención 11 — EXPERT-FUSION

*Expert 3, Extra-Trees on panel + laboratory + MRI prose; speaks only on documents that were opened* · vuelta 1

Expert 3 here — the fusion classifier. I read the panel, the mpMRI report and the laboratory panel; nothing from the previous notes or the PSA series.

SUGGESTION: NO BIOPSY   p(biopsy) = 0.27
  uncertainty  +/- 0.12 epistemic (95% band 0.03-0.50), of which 0.00 comes from values that had to be imputed
  reliability  MODERATE ('supports' tier) — out-of-fold it was right 71% of the time over the 24 labelled cases in this tier

What moved me most across the labelled series: prior positive biopsy, no prior biopsy, free PSA < 15%, DWI restriction in the report, lesion >= 15 mm in the report, suspicious DRE. Out-of-fold AUC 0.794. I am the only expert that has read the report's wording, and I still cannot see the prior grade or the
surveillance history: those are in the notes, and the registrar has to carry them.

## Intervención 12 — PANEL-PROTOCOL

*the panel's written protocol; consolidates the experts by rule and says which rule fired* · vuelta 1

The panel protocol, applied to what is on the board:

  EXPERT-STRUCTURED  DEFER, p(biopsy)=0.36  ('supports' tier)
  EXPERT-FUSION      DEFER, p(biopsy)=0.27  ('supports' tier, fusion_full)
  EXPERT-LIBRARY     DEFER, p(biopsy)=0.04  (identical panel in the series)

  documented prior grade in the opened documents: GG 3 ("Gleason 4+3")

RULE THAT FIRED: identical precedent in the labelled series — carried by EXPERT-LIBRARY.
PANEL ANSWER: NO BIOPSY. The labelled series contains this exact panel; the library returns the reading urologist's own decision for it. Out of sample this rung never fires.

Confidence the trace model expects here: clear. Weights it expects: dre=important, bx=decisive, comorbidity=noted, pirads=important, vol=noted, psad=noted, age=important, fh=noted, psa=noted.

CHAIR: this is the panel's position. You sign it, and you write why in the room's words — naming what the registrar retrieved. If you believe a retrieved finding overturns it, name that finding with its value; the burden is on the finding, not on the panel.

## Intervención 13 — VERIFIER

*second EAU reader; checks against the guideline whether this can be decided yet* · vuelta 1

SUFFICIENCY
The documents opened by the registrar appear to have addressed the moderator's questions. The `previous_notes` explicitly state the prior biopsy established "Gleason 4+3 disease," answering Q1. The notes also state, "no explicit surveillance protocol with a confirmatory biopsy due," answering Q2.

ALIGNMENT WITH THE PANEL
The retrieved evidence, specifically the documented prior grade of Gleason 4+3 and the lack of an explicit surveillance plan, aligns with the PANEL-PROTOCOL's answer of NO BIOPSY, which was driven by the EXPERT-LIBRARY precedent.

THE OPEN QUESTIONS, ONE BY ONE
Q1. What is the documented Gleason or ISUP grade of the prior positive biopsy? Answered by the `previous_notes`: Gleason 4+3.
Q2. Is the patient currently on a surveillance protocol with a confirmatory biopsy due? Answered by the `previous_notes`: No explicit surveillance protocol was noted.

WHAT CARRIES WEIGHT, AND WHY
The documented prior biopsy grade (Gleason 4+3) is highly relevant as it is the established prior diagnosis. The lack of an explicit surveillance protocol is also critical as it speaks to the current management context.

MY SUGGESTION TO THE CHAIR
I suggest the decision should remain NO BIOPSY, as the retrieved facts confirm the panel's conclusion based on the documented prior diagnosis and surveillance status.

VERDICT: ready | SUGGEST: defer | MISSING: none

[The conference closes after pass 1: the verifier called the record ready. The chair decides on the record as it stands.]

## Intervención 14 — CHAIR

*the senior urologist who signs the decision* · vuelta 1

MY DECISION: NO BIOPSY   (confidence: clear)

The decision is to defer biopsy because the panel protocol was driven by an identical precedent in the labelled series, which concluded with no biopsy. This conclusion is supported by the retrieved facts that the prior biopsy established Gleason 4+3 disease, and there was no explicit surveillance protocol noted. The evidence converged on deferral based on the documented prior diagnosis, which is the most relevant factor in this situation.

What carried weight: dre=important, bx=decisive, comorbidity=noted, pirads=important, vol=noted, psad=noted, age=important, psa=noted
Documents this conference opened: radiology_report, psa_trend, previous_notes, laboratory_results
